Insights
Baseimmune, based in London, leverages advanced AI to revolutionize vaccine development, offering a competitive edge in the biotech sector. Their B2B SaaS model aligns with industry trends favoring digital transformations and efficiencies. Unlike traditional methods, Baseimmune's AI algorithms enable faster and more effective vaccine creation, addressing issues like delayed outbreak responses. Backed by investors such as Hoxton Ventures and Merck Global Health Innovation Fund, Baseimmune is well-positioned for significant growth and impact in healthcare.
Investors
Hoxton Ventures Series A
IQ Capital Partners Series A
IQ Capital Partners Series A
Maki.vc Series A
Merck Global Health Innovation Fund Series A
Cherry Ventures Seed
Creator Fund Seed
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable